Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis

被引:26
作者
Lau, DHM [1 ]
Yang, BJ [1 ]
Hu, RD [1 ]
Benfield, JR [1 ]
机构
[1] NO CALIF HLTH SYST VET ADM,SACRAMENTO,CA
关键词
synchronous lung cancers; p53; K-ras; polymerase chain reaction (PCR); nonradioisotopic single-strand conformation polymorphism (SSCP); DNA sequencing;
D O I
10.1097/00019606-199708000-00001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Disease stage is the most important factor in determining prognosis and treatment of lung cancer. Staging of lung cancer is complicated by presentation of multiple pulmonary malignant lesions with a similar histology. It is a dilemma to decide if these lesions are synchronous primaries arising from different malignant clones or metastases from a single clone. Lung cancer is associated with multiple genetic abnormalities including mutations of K-ras and p53, which are believed to occur prior to onset of metastasis. To determine the clonal origin of multiple pulmonary malginant nodules, we analyzed point mutations of K-ras and p53 by microdissection, polymerase chain reactions (PCR), nonradioisotopic single-strand conformation polymorphism (SSCP) analysis, and DNA sequencing. Each pulmonary lesion was microdissected from paraffin slides. Genomic DNA was amplified by two sequential PCRs followed by electrophoresis in a minigel and silver staining. Deoxyribonucleic acid sequencing was performed if necessary to confirm a mutation found upon SSCP analysis. Applying this molecular approach, we were able to differentiate the clonal origins of multiple malignant nodules of the lung as exemplified by the two cases presented.
引用
收藏
页码:179 / 184
页数:6
相关论文
共 24 条
[1]  
CHUNG KY, 1993, CANCER RES, V53, P1676
[2]  
DESCHAMPS C, 1990, J THORAC CARDIOV SUR, V99, P769
[3]   SYNCHRONOUS PRIMARY LUNG CANCERS [J].
FERGUSON, MK .
CHEST, 1993, 103 (04) :S398-S400
[4]  
FIGLIN RA, 1995, CANC TREATMENT, P385
[5]  
GABRIELLA S, 1995, CANCER RES, V55, P135
[6]  
Gazdar Adi F., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P690
[7]   GENDER COMPARISONS IN HUMAN LUNG-CANCER - ANALYSIS OF P53 MUTATIONS, ANTI-P53 SERUM ANTIBODIES AND C-ERBB-2 EXPRESSION [J].
GUINEE, DG ;
TRAVIS, WD ;
TRIVERS, GE ;
DEBENEDETTI, VMG ;
CAWLEY, H ;
WELSH, JA ;
BENNETT, WP ;
JETT, J ;
COLBY, TV ;
TAZELAAR, H ;
ABBONDANZO, SL ;
PAIROLERO, P ;
TRASTEK, V ;
CAPORASO, NE ;
LIOTTA, LA ;
HARRIS, CC .
CARCINOGENESIS, 1995, 16 (05) :993-1002
[8]  
KISHIMOTO Y, 1992, CANCER RES, V52, P4799
[9]  
KRAEGEL SA, 1992, CANCER RES, V52, P4724
[10]  
LEHMAN TA, 1991, CANCER RES, V51, P4090